Health finance news 2026: healthcare stocks, policy and digital health funding

Last revised: Nov 16, 2026 · By the FintechZoom Markets Desk, reviewed under our editorial policy

Health finance news 2026 has three threads: a late-year rally in healthcare stocks, a heavy run of federal policy changes that hit insurers, hospitals and drugmakers in 2027, and a steadier flow of venture money into digital health. The State Street Health Care Select Sector SPDR ETF (XLV) returned 20.92% on a NAV basis in 2026 through Oct 31, up from 10.07% through Sep 30, and Eli Lilly made up 16.75% of the fund on Nov 12 (State Street XLV fund page). Lilly raised its 2026 revenue guidance to $91.0 billion to $92.0 billion on Oct 29 (Lilly Q3 2026 release (SEC)). ACA marketplace benchmark premiums rise 13% on average for 2027 after the enhanced premium tax credits expired (KFF, Nov 6, 2026), Medicaid work requirements start by Jan 1, 2027 (KFF work requirements brief), and US digital health startups raised $11.1 billion in the first nine months of 2026 (Rock Health, Oct 9, 2026).

Health finance news 2026: dated timeline

The table lists the events behind this update in date order. Each row links to the source in the sections below.

Date (2026)EventWho it affects
Feb 3Consolidated Appropriations Act, 2026 extends Medicare telehealth flexibilities through Dec 31, 2027Telehealth providers, digital health
Apr 1FDA approves Lilly’s oral GLP-1 Foundayo (orforglipron) for obesityLilly, Novo Nordisk, payers
Apr 6CMS finalizes 2027 Medicare Advantage payments: average +2.48%UnitedHealth, Humana, other MA insurers
Late MayIRS publishes 2027 HSA limits ($4,500 self-only, $9,000 family)HSA savers, employers
Sep 29Section 232 tariffs on patented drug imports extend to all branded drugmakersPharma importers
Oct 9Rock Health: $11.1B in digital health venture funding Q1 to Q3Digital health startups, investors
Oct 13UnitedHealth and Johnson and Johnson report Q3 and raise 2026 guidanceLarge-cap healthcare
Oct 29 to 30Lilly and AbbVie report Q3 and raise 2026 guidanceLarge-cap pharma
Nov 1ACA open enrollment for 2027 coverage begins in most statesMarketplace enrollees, insurers
Nov 4CMS final 2027 physician fee schedule; Novo Nordisk Q3 resultsPhysician groups, Novo Nordisk
Nov 30Statutory deadline for CMS to publish negotiated prices for the third cycle (effective 2028)15 drugs in Part B and Part D

Live chart of XLV and five large healthcare stocks from TradingView. Prices update through the trading day; the dated figures in the text come from the sources cited.

Healthcare stocks in 2026: XLV and the large names

XLV is a simple gauge of how large US healthcare companies have traded in 2026. State Street lists a gross expense ratio of 0.08%, assets of $50.57 billion and 61 holdings, with a NAV of $187.72 on Nov 12, 2026 and a 30-day SEC yield of 1.34% (State Street XLV fund page). The fund tracks the Health Care Select Sector Index, which holds the healthcare members of the S&P 500.

XLV NAV total returnThrough Sep 30, 2026Through Oct 31, 2026
Year to date10.07%20.92%
1 year22.88%30.34%
3 years (annualized)11.17%15.97%
5 years (annualized)7.47%8.42%

Source: State Street XLV fund page, checked Nov 16, 2026. Past performance does not predict future returns.

Most of the 2026 gain came in October, the month Lilly, Johnson and Johnson, AbbVie and UnitedHealth reported third-quarter results and raised full-year guidance. Concentration is the point to know before buying the fund: on Nov 12 the top five holdings were Eli Lilly 16.75%, Johnson and Johnson 10.04%, AbbVie 7.64%, UnitedHealth 5.34% and Merck 5.32%, about 45% of assets in five companies (FintechZoom sum of State Street weights).

Third-quarter 2026 results from the largest healthcare names

CompanyReportedQ3 2026 revenueQ3 EPS2026 guidance after Q3
Eli Lilly (LLY)Oct 29$24.4B, +39%Reported $7.22; non-GAAP $7.48Revenue $91.0B to $92.0B (from $85B to $87B); non-GAAP EPS $35.00 to $36.00
Johnson and Johnson (JNJ)Oct 13$25.4B, +5.9%Reported $0.09; adjusted $2.59Sales $101.0B to $101.4B; adjusted EPS $11.05 to $11.15
AbbVie (ABBV)Oct 30$17.40B, +10.3%GAAP $2.37; adjusted $3.82Adjusted EPS $13.95 to $13.99 (from $13.76 to $13.96)
UnitedHealth (UNH)Oct 13$112.7B (Q3 2025: $113.2B)Reported $4.56; adjusted $4.69Adjusted EPS at least $20.50; reported at least $19.50
Novo Nordisk (NVO)Nov 4DKK 79.2B, +4% at constant currencyNot used hereAdjusted sales and operating profit growth -2% to +2% at constant currency

Sources: company releases filed with the SEC (Lilly, J&J, AbbVie, Novo Nordisk 6-K) and UnitedHealth’s Business Wire release.

Lilly’s quarter was driven by tirzepatide: Mounjaro sales were $10.7 billion (+65%) and Zepbound $5.4 billion (+49%). Volume rose 53% worldwide while realized prices fell 15%, and US prices fell 7% (Lilly Q3 2026 release (SEC)). Its non-GAAP EPS guidance went down even as revenue guidance went up, because of a $4.57 per share charge for acquired in-process R&D in the quarter.

Johnson and Johnson’s reported EPS of $0.09 includes a one-time charge for its proposed talc litigation resolution; adjusted EPS fell 7.5% while Innovative Medicine sales grew 7.7% to $16.8 billion and MedTech sales grew 2.5% to $8.6 billion (J&J Q3 2026 release (SEC)). AbbVie’s immunology drugs Skyrizi ($5.78 billion, +22.7%) and Rinvoq ($2.71 billion, +23.9%) carried its quarter (AbbVie Q3 2026 release (SEC)).

UnitedHealth’s medical care ratio fell to 88.4% from 89.9% a year earlier, helped by $610 million of favorable prior-period reserve development, and operating earnings rose to $6.6 billion from $4.3 billion (UnitedHealth Q3 2026 release (Business Wire via Finviz)). Novo Nordisk raised its 2026 range to -2% to +2% at constant currency from 0% to -6% in August, and booked about DKK 8.7 billion of impairments in the quarter (Novo Nordisk Q3 2026 report (SEC 6-K)).

Healthcare ETFs compared

XLV holds only large US healthcare companies, so a few drugmakers and insurers set its direction. The SPDR S&P Biotech ETF (XBI) weights its biotech holdings more equally, which gives small and mid-size drug developers more say and makes the fund swing harder on trial results and takeover news. The iShares Biotechnology ETF (IBB) leans toward larger biotech companies, and the iShares US Medical Devices ETF (IHI) holds device makers such as Abbott and Intuitive Surgical. Check each issuer’s page for current fees, holdings and returns before comparing them; FintechZoom has verified only the XLV figures above for this update. For broader fund choices see our best ETFs to buy in 2026 guide.

GLP-1 drugs: approvals, prices and Medicare negotiation

The FDA approved Foundayo (orforglipron), Lilly’s once-daily GLP-1 pill, on Apr 1, 2026 for adults with obesity, or overweight with weight-related conditions. It went through the Commissioner’s National Priority Voucher pilot 50 days after filing; the original PDUFA date was Jan 20, 2027 (Healio, Apr 1, 2026). Foundayo sold $184 million in the third quarter and $281 million in the first nine months of 2026 (Lilly Q3 2026 release (SEC)).

Prices are falling as volumes rise. Lilly’s US realized prices dropped 7% in the third quarter, mostly on Zepbound, and prices outside the US fell 29% after Mounjaro was added to China’s National Reimbursement Drug List (Lilly Q3 2026 release (SEC)). In Medicare, negotiated prices for 15 drugs from the second negotiation cycle take effect on Jan 1, 2027, including semaglutide sold as Ozempic, Rybelsus and Wegovy (CMS negotiation program page). KFF reports CMS estimated $12 billion in savings, or 44% net, against 2024 net prices for that cycle (KFF, Mar 11, 2026).

Health policy in 2026: who gains and who pays

Medicare Advantage and physician pay for 2027

CMS finalized a 2.48% average increase in Medicare Advantage payments for 2027 on Apr 6, 2026, worth more than $13 billion. It also stops counting diagnoses from unlinked chart reviews in risk scores from 2027, which hits plans that rely on those records most (CMS, Apr 6, 2026). KFF estimates per-enrollee payments rise nearly 5% once the upward trend in risk scores is included, about $26 billion in total (KFF, Apr 8, 2026).

Doctors face a cut. The 2027 physician fee schedule final rule, released Nov 4, 2026, sets the conversion factor at $32.63 for most clinicians, down 2.31% from $33.40, and $32.95 for qualifying APM participants, down 1.83% (AAMC summary of the CY2027 fee schedule final rule).

Drug pricing and tariffs

The third Medicare negotiation cycle covers 15 drugs and is the first to include Part B drugs given in doctors’ offices; it covers about $27 billion in gross Medicare spending, and CMS must publish the results by Nov 30 for prices that start in 2028 (KFF, Mar 11, 2026). The 2025 reconciliation law exempted orphan drugs approved for more than one rare disease, which delayed selection of Keytruda and Opdivo.

On trade, the Section 232 tariff on imported patented drugs is 100% at the standard rate. It began with 17 large drugmakers at the end of July 2026 and covered all branded drugmakers from Sep 29. Companies with an approved US manufacturing plan and a most-favored-nation pricing agreement pay 0% through Jan 20, 2029, and all 17 first-phase companies, including AbbVie, Amgen, Pfizer and Merck, had signed such agreements by Aug 31. Generics and biosimilars are exempt, and EU, Japanese, Korean and Swiss products are capped at 15% (Managed Healthcare Executive, Sep 29, 2026).

Medicaid and the ACA marketplaces

The 2025 reconciliation law signed on Jul 4, 2025 cuts federal Medicaid spending by $911 billion over ten years in CBO’s estimate, with work requirements the largest piece at $326 billion. Adults in the expansion group must log 80 hours a month of work or community service, or qualify for an exemption, starting no later than Jan 1, 2027, though HHS can give states that show good faith until Dec 31, 2028 (KFF work requirements brief).

In the ACA marketplaces, benchmark silver premiums rise 13% on average for 2027 (11% in HealthCare.gov states, 16% in state-run exchanges) after a 26% jump for 2026. Effectuated enrollment fell 12% to 19.2 million by February 2026, and CBO projects marketplace enrollment falls to 13.1 million in 2027 from a 2025 peak of 22.4 million. Open enrollment for 2027 began Nov 1, 2026 in most states (KFF, Nov 6, 2026). Hospitals with many Medicaid and marketplace patients carry the most exposure to higher uninsured rates. Democrats won both chambers of Congress in the Nov 3, 2026 midterms; whether the new Congress revisits the subsidies after it is seated in January 2027 is an open question, and our stock market after the midterm elections page covers the market side.

PolicyDateMost exposed
Medicare Advantage 2027 rate (+2.48%) and chart review exclusionFinal Apr 6, 2026; applies 2027MA insurers that rely on chart reviews
Physician fee schedule conversion factor -2.31%Final Nov 4, 2026; applies 2027Physician groups
Negotiated Medicare prices, second cycle (15 drugs)Effective Jan 1, 2027Novo Nordisk and other listed makers
Third negotiation cycle (15 drugs, Part B included)Prices due by Nov 30, 2026; effective 2028Makers of selected drugs
Section 232 tariff on patented drugsAll branded makers from Sep 29, 2026Importers without US plants or pricing deals
Medicaid work requirementsBy Jan 1, 2027 (exemptions to Dec 31, 2028)Hospitals, Medicaid managed care plans
ACA enhanced tax credits expired; 2027 premiums +13%2027 open enrollment from Nov 1, 2026Marketplace insurers, enrollees
Medicare telehealth flexibilitiesExtended through Dec 31, 2027Telehealth providers

Digital health funding in 2026

Rock Health counted $3.7 billion of venture funding across 114 deals for US digital health startups in the third quarter of 2026, and $11.1 billion across 358 deals from January to September. The average deal was $31.0 million in 2026, up from $29.5 million in 2025 and $20.6 million in 2024, and Rock Health projects the full year will pass $14.8 billion. Acquisitions held steady at 164 deals through Q3, against 172 a year earlier (Rock Health, Oct 9, 2026).

Illustration of a clinician holding a video telehealth visit with a patient on a tablet

Policy is friendlier to virtual care than it was a year earlier. The Consolidated Appropriations Act, 2026, signed Feb 3, 2026, extended Medicare telehealth flexibilities through Dec 31, 2027 (Baker Donelson, Feb 5, 2026), which removes a short-term cliff for virtual visit companies that bill Medicare. Most digital health companies in the Rock Health data are private, so public-market investors get exposure mainly through listed telehealth, device and health IT stocks, which tend to be smaller and more volatile than the XLV leaders. Our AI in finance trends 2026 page covers the wider AI investment story.

Illustration of a smartphone mental wellness app with a daily mood check-in and weekly progress chart

Personal health finance: HSAs, Medicare costs and medical debt

Health savings accounts are paired with high-deductible health plans. Contributions are deductible or pre-tax, growth is untaxed, and withdrawals for qualified medical expenses are tax-free; account holders aged 55 or older can add a $1,000 catch-up contribution (IRS Publication 969).

IRS limit20262027
HSA contribution, self-only$4,400$4,500
HSA contribution, family$8,750$9,000
HDHP minimum deductible, self-only / family$1,700 / $3,400$1,750 / $3,500
HDHP out-of-pocket maximum, self-only / family$8,500 / $17,000$8,700 / $17,400

Sources: Rev. Proc. 2025-19 for 2026 (via IFEBP) and IRS Rev. Proc. 2026-24 for 2027.

Rev. Proc. 2026-24 also sets a limit for direct primary care service arrangements in 2027: monthly fees of up to $150 for an individual, or $300 for an arrangement covering more than one person (IRS Rev. Proc. 2026-24). Our take-home paycheck calculator shows how pre-tax HSA payroll deductions change net pay.

For Medicare, the standard Part B premium was $202.90 a month in 2026. CMS had not published the official 2027 figure when AARP reported on Oct 5, 2026, and the Medicare Trustees projected $209.50 a month with a $292 deductible (AARP, Oct 5, 2026). We will update this line when CMS announces the final amounts.

On medical debt, the CFPB rule that would have kept most medical bills off credit reports never took effect: a federal judge in the Eastern District of Texas vacated it on Jul 11, 2025 (CDIA, Jul 11, 2025). Medical debt can still appear on credit reports under federal law, subject to the credit bureaus’ own reporting policies and any state rules that survive legal challenge.

What to watch next

DateEventWhy it matters
By Nov 30, 2026CMS publishes third-cycle negotiated pricesSets 2028 Medicare prices for 15 drugs, including Part B drugs
Late 2026 (date not announced)CMS 2027 Part B premium and deductibleOut-of-pocket cost for most Medicare enrollees
Jan 1, 2027Second-cycle negotiated prices, new HSA limits and Medicaid work requirement deadlineDrugmaker revenue, household budgets, Medicaid enrollment
January 2027New Congress seated after Nov 3 midtermsAny change to ACA subsidies or Medicaid rules needs new legislation
Dec 31, 2027Medicare telehealth flexibilities expire unless extended againVirtual care billing

From our desk: what we found checking this update. The April 2026 edition listed $4,300 and $8,550 as the 2026 HSA limits; those are the 2025 limits, and the IRS figures for 2026 are $4,400 and $8,750. It also described the CFPB medical debt rule as a change in force, although a federal court vacated it in July 2025. An ETF comparison graphic on the old page showed XLV with a beta of 0.06 and a Sharpe ratio of 0.63 without any source or date; we removed it and replaced it with live TradingView quotes. Market-size figures for digital health and mental health apps had no named source and were dropped. XLV’s year-to-date NAV return roughly doubled between the Sep 30 and Oct 31 fact sheets (10.07% to 20.92%), so any healthcare return figure older than November is now well out of date.

Health finance news 2026 FAQs

What is the biggest health finance news of 2026 so far?

For investors, the late-year rally in large healthcare stocks stands out: the Health Care Select Sector SPDR ETF returned 20.92% on a NAV basis in 2026 through Oct 31, after 10.07% through Sep 30, according to State Street. For households, the expiry of the enhanced ACA premium tax credits and a 13% average rise in 2027 benchmark marketplace premiums reported by KFF on Nov 6, 2026 matter most.

How have healthcare stocks performed in 2026?

The XLV fund, which holds the healthcare members of the benchmark US large-cap index, returned 20.92% year to date through Oct 31, 2026 on a NAV basis. Most of that came in October, when Eli Lilly, Johnson and Johnson, AbbVie and UnitedHealth reported third-quarter results and raised 2026 guidance. Eli Lilly was 16.75% of the fund on Nov 12, 2026.

What are the HSA contribution limits for 2026 and 2027?

For 2026 the limits are $4,400 for self-only coverage and $8,750 for family coverage. For 2027 the IRS raised them to $4,500 and $9,000 in Revenue Procedure 2026-24. People aged 55 or older can contribute an extra $1,000 in both years.

Why are ACA marketplace premiums rising for 2027?

KFF reported on Nov 6, 2026 that benchmark silver premiums rise 13% on average for 2027, following a 26% increase for 2026. The enhanced premium tax credits expired, so many enrollees pay more of the premium themselves, and effectuated enrollment fell 12% to 19.2 million by February 2026.

How much more will Medicare Advantage plans be paid in 2027?

CMS finalized an average payment increase of 2.48% for 2027 on Apr 6, 2026, worth more than $13 billion. KFF estimates per-enrollee payments rise nearly 5% once higher risk scores are included. CMS also stops counting diagnoses from unlinked chart reviews in 2027.

When do Medicaid work requirements start?

The 2025 reconciliation law requires states to start Medicaid work requirements for the expansion adult group by Jan 1, 2027. Adults must show 80 hours a month of work or community service or qualify for an exemption. HHS can give states that show a good-faith effort until Dec 31, 2028.

How much venture money went into digital health in 2026?

Rock Health counted $11.1 billion across 358 deals for US digital health startups from January to September 2026, including $3.7 billion across 114 deals in the third quarter. The average deal size was $31.0 million.

Which drugs get Medicare negotiated prices in 2027?

Fifteen Part D drugs from the second negotiation cycle get negotiated prices on Jan 1, 2027, including semaglutide sold as Ozempic, Rybelsus and Wegovy. KFF reports CMS estimated $12 billion in savings, or 44% net, against 2024 net prices.

Is this article a recommendation to buy healthcare stocks?

No. FintechZoom reports dated facts from company filings, government agencies and research groups. It does not give buy or sell ratings or price targets. Healthcare stocks can fall sharply on trial results, policy changes and pricing pressure, so check current data and your own circumstances before investing.

How we report on health finance: we use company releases and SEC filings for company figures, CMS, IRS and other agency documents for policy, fund issuer pages for ETF data, and named research groups such as KFF and Rock Health for surveys and estimates. Each figure carries its date. We do not publish price targets or buy and sell ratings.

Revision history: Nov 16, 2026 rewrite with Q3 2026 company results, XLV data to Nov 12, 2027 Medicare, ACA, Medicaid and HSA rules, Rock Health Q3 funding and corrected 2026 HSA limits; unsourced market-size figures and the unsourced ETF graphic removed. Previous edition: Apr 13, 2026.

Related: Stock market after the midterm elections · Best ETFs to buy in 2026 · Stock market news today · Business finance news today · Climate finance news 2026 · US stock market today

This article is for information only and is not investment, tax or medical advice. Figures can change after publication. Read our disclaimer.

Sources: State Street XLV fund page · Lilly Q3 2026 release (SEC) · J&J Q3 2026 release (SEC) · AbbVie Q3 2026 release (SEC) · UnitedHealth Q3 2026 release (Business Wire via Finviz) · Novo Nordisk Q3 2026 report (SEC 6-K) · Healio, Apr 1, 2026 · CMS, Apr 6, 2026 · KFF, Apr 8, 2026 · AAMC summary of the CY2027 fee schedule final rule · CMS negotiation program page · KFF, Mar 11, 2026 · Managed Healthcare Executive, Sep 29, 2026 · KFF work requirements brief · KFF, Nov 6, 2026 · Baker Donelson, Feb 5, 2026 · Rock Health, Oct 9, 2026 · IFEBP summary of Rev. Proc. 2025-19 · IRS Rev. Proc. 2026-24 · IRS Publication 969 · AARP, Oct 5, 2026 · CDIA, Jul 11, 2025

Tags :